GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.417
-0.052 (-11.14%)
Mar 9, 2026, 4:00 PM EDT - Market closed
GT Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -28.35 | -13.16 | -7.6 | -20.88 | -58.01 | |
| Loss (Gain) From Sale of Investments | - | - | -0.05 | 0.03 | 0.03 | |
| Stock-Based Compensation | 0.43 | 0.23 | 2.2 | 7.65 | 33.93 | |
| Other Operating Activities | 15.93 | -0.8 | -5.23 | -0.02 | 0.51 | |
| Change in Accounts Payable | -1.3 | 0.94 | 1.96 | -2.03 | 7.08 | |
| Change in Other Net Operating Assets | 0.38 | -0.11 | -0.14 | 0.04 | 0.86 | |
| Operating Cash Flow | -12.91 | -12.9 | -8.85 | -15.22 | -15.61 | |
| Investment in Securities | - | 12.89 | -2.01 | 12.15 | -23.04 | |
| Investing Cash Flow | - | 12.89 | -2.01 | 12.15 | -23.04 | |
| Short-Term Debt Issued | - | - | - | - | 1.21 | |
| Total Debt Issued | - | - | - | - | 1.21 | |
| Net Debt Issued (Repaid) | - | - | - | - | 1.21 | |
| Issuance of Common Stock | 5.5 | 2.98 | 6.27 | - | 41.11 | |
| Repurchase of Common Stock | - | - | - | -0.22 | - | |
| Preferred Dividends Paid | -0.23 | - | - | - | - | |
| Dividends Paid | -0.23 | - | - | - | - | |
| Financing Cash Flow | 15.78 | 2.98 | 6.27 | -0.22 | 42.32 | |
| Net Cash Flow | 2.86 | 2.97 | -4.59 | -3.3 | 3.67 | |
| Free Cash Flow | -12.91 | -12.9 | -8.85 | -15.22 | -15.61 | |
| Free Cash Flow Per Share | -2.34 | -6.80 | -6.57 | -14.32 | -16.63 | |
| Cash Interest Paid | - | - | 0.21 | - | - | |
| Levered Free Cash Flow | -12.01 | -9.62 | -4.68 | -10.91 | -0.82 | |
| Unlevered Free Cash Flow | -11.93 | -9.62 | -4.55 | -10.9 | -0.38 | |
| Change in Working Capital | -0.92 | 0.83 | 1.83 | -1.99 | 7.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.